Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8045233 | 0.80 | HTT (0.39) | AHRHTTMAPTCYP24A1TBXAS1 | |
| SCHEMBL28857423 | 0.79 | AHR (0.37) | AHRHTTCYP24A1KMT2ATBXAS1 | |
| Iodomethane SCHEMBL22712578 | 0.77 | AHR (0.37) | AHRHTTMAPTCYP24A1TBXAS1 | |
| SCHEMBL1171099 | 0.76 | AHR (0.42) | AHRHTTTBXAS1ALDH1A1 | |
| SCHEMBL165658 | 0.76 | HTT (0.40) | AHRHTTTBXAS1ALDH1A1 | |
| SCHEMBL1527981 | 0.75 | AHR (0.43) | AHRTBXAS1 | |
| SCHEMBL9913328 | 0.74 | CYP24A1 (0.37) | AHRHTTMAPTCYP24A1TBXAS1 | |
| SCHEMBL10951816 | 0.73 | AHR (0.49) | AHRTBXAS1ALDH1A1 | |
| SCHEMBL1528059 | 0.73 | AHR (0.41) | AHRTBXAS1ALDH1A1 | |
| SCHEMBL411293 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3192795-B1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10464930-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-11-05 | — | — | US | disclosed |
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3209641-A2 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR AND THE TREATEMENT OF DISEASE | Lycera Corporation (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3192795-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | The Board of Trustees of the University of Illionis (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
| US-20170114052-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-04-27 | — | — | US | disclosed |
| US-20170114052-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-04-27 | — | — | US | disclosed |
| US-20150284357-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
| US-20150284357-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464930-B2 | Compositions and methods for treating estrogen-related medical disorders | HSD17B11, CYP19A1, ESR1 | AHR 2043/4885HTT 3471/4885MAPT 1855/4885 |
| US-20150284357-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, CYP19A1, ESR1 | AHR 2043/4885HTT 3471/4885MAPT 1855/4885 |
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORB, RORA | AHR 5/4885HTT 2972/4885MAPT 3446/4885 |
| US-20170114052-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, CYP19A1, ESR1 | AHR 2043/4885HTT 3471/4885MAPT 1855/4885 |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | AHR 7/4885HTT 3447/4885MAPT 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.